Idecabtagene Vicleucel

gene therapy

Identifier: CI-DRUG-00000744
Entity page: /drug/idecabtagene-vicleucel ↗
Edges: 25

Neighbours: 8 cancers1 genes10 trials1 approvals
Drawn: 20 of 20 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Idecabtagene Vicleucel approved for …APPROVED_FOR2 of 1
→ approved for	Multiple Myelomahematologic_malignancy	supports	EMA indication text	Multiple Myeloma	1	Regulatory	ema	graph →
→ approved for	Health Canada · CAMarketed in Canada as ABECMA (DIN 02516233) under ATC L01XL07 IDECABTAGENE VICLEUCEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Idecabtagene Vicleucel targets …TARGETS1 of 1
→ targets	TNFRSF17	—	BINDING AGENT	—	1	Curated	chembl	graph →

Idecabtagene Vicleucel targets …TARGETS1 of 1

→ targets

TNFRSF17

—

BINDING AGENT

—

Curated

Idecabtagene Vicleucel investigated for …INVESTIGATED_FOR3 of 3
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Multiple Myelomahematologic_malignancy	unknown	4	Multiple Myeloma	1	Curated	chembl	graph →
→ investigated for	Plasma Cell Neoplasmhematologic_malignancy	unknown	4	Plasma Cell Neoplasm	1	Curated	chembl	graph →

Idecabtagene Vicleucel investigated in trials for …INVESTIGATED_IN_TRIALSderived6 of 6
→ investigated in trials for	Multiple Myelomahematologic_malignancy 13 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Multiple Myeloma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemia 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	AL Amyloidosis 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	AL Amyloidosis	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemia 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Plasma Cell Leukemia 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Plasma Cell Leukemia	1	Observed	clinicaltrials	graph →

Idecabtagene Vicleucel studied in …STUDIED_INderived10 of 14show all (up to 200)
→ studied in	NCT06855121recruiting The Norwegian Immunotherapy in Multiple Myeloma Study · 14 trials list this drug (7 active)	—	—	Multiple Myeloma,Plasma Cell Leukemia,AL Amyloidosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT04855136Phase 1 · terminated Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma · 14 trials list this drug (7 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03651128Phase 3 · completed Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) · 14 trials list this drug (7 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05032820Phase 2 · completed Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma · 14 trials list this drug (7 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05393804Phase 2 · active not recruiting A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant · 14 trials list this drug (7 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06045806Phase 3 · active not recruiting A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation · 14 trials list this drug (7 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03601078Phase 2 · completed An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma · 14 trials list this drug (7 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03642626Phase 2 · active not recruiting MT2017-45: CAR-T Cell Therapy for Heme Malignancies · 14 trials list this drug (7 active)	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT06357754recruiting Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy · 14 trials list this drug (7 active)	—	—	Multiple Myeloma,Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03361748Phase 2 · completed Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma · 14 trials list this drug (7 active)	—	—	Multiple Myeloma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths